Changes Brewing At Bayer, But Pharma Strategy Remains On Point
Executive Summary
Bayer AG is pursuing an acquisition of seed manufacturer Monsanto Co. that would establish agriculture as the largest business unit within the diversified life sciences company, usurping pharmaceuticals as the top revenue generator. Bayer Head of Innovation Kemal Malik said the company’s commitment to pharmaceuticals remains unwavering despite the M&A play.
You may also be interested in...
Bayer Reiterates Pharma Commitment Post-Monsanto, Plays Up Pipeline
German conglomerate says five recent launches led by Xarelto and Eylea are expected to bring in more than $11bn in peak sales, a 33% increase over previous projections. CEO Baumann pledges to make the investments needed to continue growing the pharma business.
European Notebook: Bayer Bids For Monsanto; Biosimilar Uptake Still Sluggish; EMA Enters Drug Pricing Debate
The restructuring of business portfolios occupies Europe's big pharma companies, while the region's health providers look to improve the uptake of biosimilars, and European regulators suggest ways to use greater market competition to tame high drug prices. Plus Brexit, trade agreements, pharmacovigilance and more in this month's column.
Bayer Thins R&D Pipeline, Backs Finerenone In Kidney But Not Heart Disease
Germany’s leading pharmaceutical company Bayer has taken future competition into account when stopping the Phase III development of finerenone for congestive heart failure, and targeting specific CHF patients for treatment with another potential cardiovascular, vericiguat.